Ligand validation:4XV2

P06: Dabrafenib

P06 is a Ligand Of Interest in 4XV2 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4XV2_P06_A_801	71%	30%	0.158	0.981	1.34	1.44	3	7	2	0	100%	1
4XV2_P06_B_801	67%	29%	0.174	0.983	1.37	1.45	3	7	1	0	100%	1
5CSW_P06_B_801	38%	22%	0.232	0.936	0.96	2.27	1	11	0	0	100%	1
5HIE_P06_B_801	74%	20%	0.154	0.986	0.91	2.46	2	13	1	0	100%	1
6HJ2_P06_A_501	19%	2%	0.21	0.803	4.03	2.48	10	9	2	0	100%	0.85
7RIV_P06_A_501	7%	15%	0.382	0.843	1.97	1.82	6	10	5	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.